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Abstract: Venous thromboembolism (VTE) is a significant cause of mortality in patients with lung
cancer. Despite the availability of a wide range of anticoagulants to help prevent thrombosis,
thromboprophylaxis in ambulatory patients is a challenge due to its associated risk of haemorrhage.
As a result, anticoagulation is only recommended in patients with a relatively high risk of VTE.
Efforts have been made to develop predictive models for VTE risk assessment in cancer patients, but
the availability of a reliable predictive model for ambulate patients with lung cancer is unclear. We
have analysed the latest information on this topic, with a focus on the lung cancer-related risk factors
for VTE, and risk prediction models developed and validated in this group of patients. The existing
risk models, such as the Khorana score, the PROTECHT score and the CONKO score, have shown
poor performance in external validations, failing to identify many high-risk individuals. Some of the
newly developed and updated models may be promising, but their further validation is needed.
Keywords: venous thromboembolism; lung cancer; thromboprophylaxis; anticoagulant; risk prediction;
risk assessment; risk model; prediction rules; risk factors
1. Background and Introduction
Cancer is a major risk factor for venous thromboembolism (VTE), which includes deep
vein thrombosis and pulmonary embolism. VTE has an annual incidence of around 0.5%
in cancer patients compared to around 0.1% in the general population [1]. The incidence
of VTE in patients with cancer varies with cancer type, stage, and aggressiveness [2].
Among all cancer types, lung cancer has the second highest risk of VTE [3]. In cohort
studies, the incidence of VTE in patients with lung cancer receiving chemotherapy was
variously reported as 16.8% at three months and 14.1% at six months after the start of
chemotherapy [4], and 13.9% after a median follow-up period of 12 months [5]. Having a
VTE is a significant predictor of death within 2 years in patients with primary lung cancer,
with hazard ratios (HRs) of 2.3 (95% CI 2.2–2.4) and 1.5 (95% CI 1.3–1.7) for non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), respectively [6]. This matter
highlights the importance of the identification of patients at risk of developing VTE so that
therapeutic or preventive measures are implemented in a timely manner.
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Thromboprophylaxis is suggested in hospitalised patients with lung cancer and those
undergoing surgery, but the use of primary prevention of VTE in ambulatory patients
with lung cancer is still debatable [7]. Choice of the anticoagulation therapy is particularly
challenging in patients undergoing antineoplastic chemotherapy. On one hand, these
patients are at risk of VTE over the course of therapy and beyond. On the other hand,
anticoagulation is associated with a high bleeding risk, which could be life-threatening [8].
Low-molecular-weight heparins (LMWH) can reduce the risk of VTE, but current practice
guidelines do not recommend their routine use, while direct-acting oral anticoagulants
(DOACs) are an interesting alternative to LMWH in cancer patients [9–11]. Recent studies
have confirmed their efficacy and safety in these patients [12]. Scientific societies such
as the National Comprehensive Cancer Network (NCCN), the International Society on
Thrombosis and Haemostasis (ISTH), and more recently, the American Society of Clinical
Oncology (ASCO) and The International Initiative on Thrombosis and Cancer (ITAC) have
supported the use of DOACs [9–11]. Nevertheless, the use of DOACs in this scenario
should be carefully weighed against the bleeding risk, as evidence for higher risks of
bleeding has emerged in studies of the general cancer population [13] and in patients
starting chemotherapy [14]. As a result, it is recommended that anticoagulation is only
offered to patients with a high risk of VTE, and for this we need to have robust and reliable
risk assessment tools [15]. This requires a thorough understanding of the VTE risk factors
and clinical prediction models to identify high-risk patients.
Clinical prediction models are epidemiological/statistical tools, which use a small
number of parameters (related to the individual, or the disease, or the treatment) to estimate
a likelihood in which a specific outcome (e.g., VTE) could happen. Prediction models can
help clinicians better understand the individual patient’s conditions or risks, so they are
able to devise a personalised treatment regimen for them [16]. In 2008, Khorana et al.
established a predictive model to assess individual risk of VTE in ambulatory cancer
patients receiving chemotherapy [11]. With this model, patients are assigned to one of
three risk groups: low (score = 0), intermediate (score = 1–2) and high risk (score ≥ 3) [17].
Using this model, patients with lung cancer are stratified as either intermediate or high
risk of developing VTE [17]. The pooled data from 45 studies including various types of
cancer showed that only 23.4% (95% CI: 18.4–29.4%) of the patients who developed VTE
in the first six months had been classified as being at high risk according to the Khorana
score [18]. This poor performance led to the development of several modifications for the
Khorana score over the years, including the Vienna Modification [19], PROTECHT [20],
CONKO [21], and COPASS-CAT [22], with varying degrees of predictive ability. In this
article, we have reviewed the risk factors for VTE in ambulatory patients with lung cancer,
discussed some main risk assessment models for VTE in this group of patients, and reflected
upon advantages and disadvantages of the models. We have also explored literature gaps
and provided suggestions for further research.
2. VTE Risk Factors in Ambulatory Patients with Lung Cancer
Risk factors for VTE are grouped into three categories: patient-related, cancer-related,
and biomarkers [1]. Regarding the patient-related risk factors for VTE, co-morbidities such
as atrial fibrillation, chronic kidney disease [23], cardiovascular conditions, and overweight
or obesity [24] increase the risk of VTE. Smoking [25] and recent hospitalisation [23,24] also
raise the risk of VTE. It is believed that the Asian race has a lower risk than other races [26].
Factor V Leiden and prothrombin 20210A mutations are relatively common in Caucasians
whereas they are very rare in Asians [27,28]. These mutations have been identified as
additional risk factors for VTE in cancer patients [3]. Cancer patients carrying Factor
V Leiden mutation or prothrombin 20210A mutation had a 12.1-fold (95% CI 1.6–88.1)
and2.3-fold (95% CI 1.6–3.3) higher risk of VTE, respectively [3].
Similar to variations in the observed VTE risk among other types of cancer [3], some
subtypes of lung cancer have higher risks of VTE compared to others; for example, lung
adenocarcinoma had a higher risk of VTE occurrence than squamous cell carcinoma [6].
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However, within the NSCLC group, the association of oncogene mutations with the risk
of VTE is debatable. A systematic review by Liu et al. of 20 retrospective studies showed
that anaplastic lymphoma kinase (ALK) mutation has a higher risk of VTE than epidermal
growth factor receptor (EGFR) mutation [29], while another systematic review by Alexander
et al. reported that EGFR mutation was the strongest risk factor for VTE in patients with
lung cancer [30]. Several studies showed patients with an ALK mutation had a higher VTE
risk than those without [31], with a hazard ratio of 2.47 (95% CI 1.04–5.90) for VTE in a
median follow-up period of 7.5 months (95% CI 3.1–15.4 months) [32] or increasing the
risk of VTE by 3 to 5 times over a median follow-up period of 22 months comparing to
the general NSCLC population [33]. One possible reason is the expression of tissue factor
(TF) gene was elevated in around 41.7% of ALK-positive, but only 11.5% of ALK-negative
tissue in patients with lung cancer (p = 0.015) [34]. On the other hand, the prospective
interventional studies using ALK inhibitor found a lower incidence of VTE than that in
retrospective studies, which may be due to reduced use of chemotherapy [35].
Cancer treatment is a strong risk factor for VTE, and commonly used chemotherapy
drugs can increase the risk of this clinical condition [25,26,36]. For example, gemcitabine-
based chemotherapy increases the risk of VTE, with a reported odds ratio of 3.37 (95% CI
1.09–10.39) [23]. In addition, VTE was more likely to occur within the first six months of the
commencement of standard chemotherapy [24]. In terms of the mechanisms involved, they
are probably related to vascular endothelial damage caused by chemotherapy, especially in
patients who receive the medications through central venous catheterisation over a long
period [25,26,36].
There are a limited number of studies which have investigated the impacts of novel
anti-cancer treatments on the haemostatic system. For instance, in patients treated with
immune checkpoint inhibitors (ICIs), the cumulative incidence of VTE over a median follow-
up of 8.5 months was 12.9% (95% CI 8.2–18.5%) [37]. Sato et al. found that in patients with
NSCLC, anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1)
monoclonal antibodies might impose procoagulant effects on the haemostatic system [38].
It has been reported that the activation of T-cells in vitro induced the production of TF
in high-PD-L1-expressed monocytes [38]. Additionally, in cancer patients receiving ICIs,
some biomarkers such as vascular cell adhesion molecule 1 (sVCAM-1) and interleukin
8 (IL-8) were associated with the occurrence of VTE [39]. The administration of ICIs and
associated biomarkers have not been investigated in a VTE risk model yet, and they may
be considered as candidates for a new predictive model, although the feasibility of the
measurements could be a problem in clinical settings.
Some tissue or blood biomarkers have been found to have significant associations with
hypercoagulable conditions in patients with cancer; therefore, they could be considered as
candidate predictors in VTE risk assessment. For instance, platelets and von-Willebrand
factor (vWF) not only play vital roles in preventing blood loss following a blood vessel
injury by facilitating coagulation [40], but also contribute to thrombosis as well as cancer
metastasis [15,41]. It has been reported that high platelet counts and/or increased platelet
activity can increase the risk of developing VTE in patients with cancer [17,42]. Additionally,
elevated levels of plasma vWF, particularly the high molecular weight multimers, can
induce the formation of vWF-mediated platelet thrombi by facilitating platelet aggregation
under high shear rate conditions [43]. In different studies, high plasma vWF was associated
with the occurrence of VTE in cancer patients [44,45]. Meanwhile, increased levels of
thrombin-antithrombin III complex (TAT) (mean 4.7 [95% CI 4–6] vs. 2.5 [95% CI 2–3] µg/L,
p < 0.0001) and elevated prothrombin fragment 1+2 (F1+2), as a by-product of thrombin
generation (mean 267 [95% CI 244–289] vs. 183 [95% CI 171–196] pmol/L, p < 0.00001)
have been reported in primary lung cancer patients with VTE [46]. In addition, increased
levels of D-dimer and plasmin-α2-antiplasmin inhibitor complex (PIC) [47], generated
in fibrinolysis, and serum ionised calcium have shown associations with the occurrence
of VTE in patients with lung cancer [48]. Other biomarkers or laboratory parameters,
such as fibrinogen, activated partial thromboplastin time (aPTT) and albumin, showed
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associations with VTE [49,50], but are lacking external validation of their predictive roles.
Most biomarkers, as predictors of VTE, have been typically used at the diagnosis of cancer
or before the beginning of chemotherapy, whereas D-dimer has also been investigated in
longitudinal studies following the diagnosis [30,51]. Some biomarkers have been studied
as predictors of VTE and have been used for prediction model development. For example,
platelet count, white cell count and haemoglobin have been incorporated into the Khorana
score [17], although their effects on the occurrence of VTE in patients with lung cancer are
controversial [30].
Inflammatory mediators (particularly those cytokines which are associated with vas-
cular inflammation) are another group of biomarkers which could be used as predictors for
new VTE prediction model development. Cancer cells produce and secrete inflammatory
cytokines such as interleukin 1 (IL1), tumour necrosis factor alpha (TNF-α) and vascular en-
dothelial growth factor (VEGF), which mediate interactions between cancer cells and host
cells, including endothelial cells, platelets, monocytes and neutrophils [52]. Furthermore,
the blood levels of intracellular granular proteins or surface-expressed proteins released
from the activated host cells [15], including procoagulant platelets [53], may be used as
predictors of a hypercoagulable status in patients with solid tumours [52]. For instance,
activated monocytes in cancer patients produced more TF than resting monocytes [15]. Ad-
ditionally, neutrophil elastase (NE) released by activated neutrophils showed correlations
with aPTT, D-dimer, TAT, PIC and fibrinogen levels in lung cancer patients, with stronger
correlations seen in NSCLC [54].
3. Risk Prediction Models for VTE in Patients with Cancer
Risk prediction models, also referred to as risk assessment tools or clinical prediction
rules, are prognostic models, which use predictors to estimate the probability for individ-
uals to develop a condition in the future [55]. This review covers the particulars of some
available VTE risk prediction models which have been developed and/or validated in
ambulatory patients with lung cancer. A summary of the main features can be found in
Table 1.
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(Khorana, 2008) [17] various
Cancer tissue:
Score ≥ 3 #
Alexander 2019 [51] NSCLC• Very high-risk site
(stomach, pancreas) 2
• High-risk site (lung, lymphoma,
gynaecologic, bladder, testicular) 1 van Es 2020 [58] Various (lung cancer 58%)
Platelet count ≥ 350 × 109/L 1 Vathiotis 2018 [56] Lung adenocarcinoma
Haemoglobin < 100 g/L and/or use of ESA 1 Kuderer 2018 [25] Lung cancer (84% NSCLC)
Leukocyte count >11 × 109/L 1 Rupa-Matysek 2018 [23] Lung cancer (97/118 NSCLC)
BMI ≥ 35 kg/m2 1 Mansfield 2016 [57] Lung cancer (87.1% NSCLC)
PROTECHT
(Verso 2012) [20] various
As Khorana Score, but
Score ≥ 3
Alexander 2019 [51] NSCLC
adds gemcitabine chemotherapy, and 1
Rupa-Matysek 2018 [23] Lung cancer (NSCLC 97/118)
platinum chemotherapy 1
CONKO
(Pelzer 2013) [21] various
As Khorana Score, but s
Score ≥ 3
Alexander 2019 [51] NSCLC
removes BMI ≥ 35 kg/m2, and
Rupa-Matysek 2018 [23] Lung cancer (NSCLC 97/118)







Spyropoulos 2020 [60] Various (29.05% lung cancer)
Time since cancer diagnosis ≤ 6 months 4
Central venous catheter 3
Advanced stage of cancer 2
Cardiovascular risk factors present 5 Syrigos 2018 [24] Lung adenocarcinoma
Hospitalisation for acute medical Illness 2
Score ≥ 11 Rupa-Matysek 2018 [23] Lung cancer (97/118 NSCLC)A history of VTE 1
Platelet count ≥ 350 × 109/L 2
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Procoag-PPL < 44 s, and
MRI < 125 nM/min 1 † score = 1
HS D-dimer
(Ferroni 2012) [59] Lung cancer







(Alexander 2019) [51] NSCLC
Baseline fibrinogen ≥ 4.0 g/L and baselie





NSCLCBaseline D-dimer ≥ 1.5 mg/L 1
Month-1 D-dimer ≥ 1.5 mg/L 1
# Score ≥ 2 was used to stratify high-risk patients in the CASINI clinical trial of primary thromboprophylaxis and has been incorporated into ASCO Guideline. † binary scoring: score = 1 if Procoag-PPL < 44 s
and MRI < 125 nM/min; score = 0 if Procoag-PPL > 44 s or MRI >125 nM/min. VTE: venous thromboembolism; ESA: erythropoiesis stimulating agents; BMI: body mass index; NSCLC: non-small cell lung cancer;
ECOG PS: Eastern Cooperative Oncology Group performance status; Procoag-PPL: procoagulant phospholipid-dependent clotting time; MRI: mean rate index of thrombin generation; HS: high-sensitive.
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3.1. The Khorana Score
The Khorana Score is the first and most frequently investigated VTE risk prediction
model in patients with cancer. It uses the following five predictors: cancer site, platelet
count, leucocyte count, haemoglobin, and body mass index (BMI). In assessing an indi-
vidual’s VTE risk, 2 points are assigned for very high-risk cancer types (e.g., stomach and
pancreas), 1 point for high-risk cancer (e.g., lung, lymphoma, gynaecological, bladder,
testicular), 1 point for baseline platelet count ≥ 350 × 109/L, 1 point for baseline leuko-
cyte count > 11 × 109/L, 1 point for baseline haemoglobin level < 100 g/L or the use of
erythropoietin, and 1 point for BMI ≥ 35 kg/m2 (Table 1) [17]. The main advantage of the
Khorana score is that all the predictors used are among the routinely measured clinical
or laboratory parameters. Additionally, this score has a high specificity. However, the
score has a poor sensitivity. Multiple studies showed a low sensitivity of 10–25%, a high
specificity of 76–100%, and a poor discrimination (C-index) of about 0.50 with the high-risk
threshold of 3 points in ambulatory patients with lung cancer [23,25,51,56,57].
On the other hand, a subgroup analysis between lung cancer and non-lung cancer
patients (including colorectal, pancreatic, stomach, ovarian, breast, brain and bladder
cancers) showed a different discriminatory performance for the Khorana score [58]. The
dichotomous Khorana score did not identify higher risk of VTE compared with low–
moderate risk in ambulatory patients with lung cancer in a meta-analysis (OR = 1.1,
95% CI 0.72–1.7), whereas it was a strong predictor for other types of cancers (OR = 3.2,
95% CI 1.8–5.6, p for interaction = 0.002) [58]. This finding emphasises the need for a better
VTE model for ambulatory patients with lung cancer.
Recently, a change in the high-risk threshold from 3 to 2 of the Khorana score was
introduced and used in randomised controlled trials of direct inhibitors of Factor Xa
in ambulatory patients with cancer at a high risk of VTE [9,61]. In the stratified group
with a Khorana score ≥ 2, apixaban lowered incidence of VTE with increasing major
bleeding risk [9], while rivaroxaban did not lower incidence of VTE significantly [61]. This
cut-off value of the Khorana score has been adopted in the latest ASCO guidelines for
thromboprophylaxis in cancer (recommended for patients with a Khorana score of 2 or
higher) [10]. However, so far, the latter threshold is yet to be validated in a homogeneous
lung cancer population.
3.2. Modifications of the Khorana Score
Since its introduction in 2008, the Khorana model has been modified multiple times
by the addition and/or replacement of biomarkers. For example, by adding D-dimer and
soluble P-selection to it, the Vienna Modification (CATS score) was introduced in 2010 [19].
Later, by the addition of treatment-related factors, such as gemcitabine or platinum-based
chemotherapy, the PROTECHT score was developed [20]. By the addition of World Health
Organisation (WHO) performance status and omission of BMI, the CONKO score was
developed in patients with advanced pancreatic cancer [21]. More precisely, the PRO-
TECHT score adds 1 point for each of gemcitabine or platinum chemotherapies, and the
CONKO score removes BMI but adds the Eastern Cooperative Oncology Group (ECOG)
performance status (PS) ≥ 2 for 1 point, while the cut-off value is still 3 points in both
scores (Table 1).
The PROTECHT score and the CONKO score have been validated in ambulatory
patients with lung cancer [23,51]. Compared to the Khorana score, more patients (22–48%)
were categorised into the high-risk group by the CONKO score and even more so by the
PROTECHT score (52–64%), but there was no significant difference in the incidence of VTE
between high- and low-risk groups stratified by either of these models. A C-index around
0.50 consistently showed a poor discrimination for both models [23,51].
The VTE risk prediction model developed by Ferroni et al. is another extension of the
Khorana model with an additional predictor, which is high-sensitive D-dimer (Table 1) [59].
According to the Khorana score, patients with lung cancer are given a score of 1 point or
more, having either intermediate or high risks for VTE [17]. This model is not applicable
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to all ambulatory patients with lung cancer, but only to those with an intermediate risk
of VTE stratified by the Khorana score. A high-sensitive (HS) D-dimer level is used to
select patients with a higher risk of VTE from those within the intermediate risk group
stratified by a Khorana score of 1–2 points [59]. This study compared the relatively high-
risk subgroup to the relatively low risk subgroup within the Khorana intermediate risk
group. With a threshold of 1500 ng/mL for HS D-dimer at baseline, both sensitivity and
specificity were moderate at 81.3% and 68.5%, respectively, with a moderate discriminating
capacity of 0.704 [59].
There are also some other types of VTE risk models, such as a simple model with
only two factors including distant metastases and platinum therapy [62], and a model
using cancer site and continuous D-dimer concentration rather than a cut-off value, called
the CATS-MICA model [63]. Neither of these risk prediction models has been externally
validated in patients with lung cancer.
3.3. The COMPASS-CAT Score
The COMPASS-CAT score is a more complicated model with both cancer-related and
patient-related factors, which are anthracycline treatment (6 points), time since cancer
diagnosis ≤ 6 months (4 points), central venous catheter use (3 points), advanced stage of
cancer (2 points), cardiovascular risk factors present (5 points), recent hospitalisation for
acute medical illness (2 points), a history of VTE (1 point), and platelet count ≥350 × 109/L
(2 points) (Table 1) [22]. This score has been validated in ambulatory patients with lung
cancer, but two different cut-off values for risk stratification have been used in different
studies [23,24,60]. The percentage of high-risk patients was 90% and 71% with a cut-off
value of 7 and 11, respectively. There was an obvious difference in the incidence of VTE
between high- and low-risk groups, which was 10.8% vs. 6.6% (p value not reported) and
23.8% vs. 0% (OR 9.65 [95% CI 1.24–75.24], p = 0.031) in the models with the cut-off values
of 7 and 11, respectively [23,60].
Compared to the Khorana score and its variations, the COMPASS-CAT score had a
higher sensitivity, which was 83% and 100% with a cut-off value of 7 and 11, respectively.
However, the specificity decreased to 35–51%, which means about one-half to two-thirds of
patients who did not develop VTE had been classified as high risk [23,24]. The COMPASS-
CAT score with the cut-off value of 11 showed a high discrimination with a C-index of
0.89 [23]; however, with the change in the cut-off value from 7 to 11 this model needs
further validation.
The varying performance between these models may reflect the composite of the dif-
ferent categories of predictors and their weights. The COMPASS-CAT score only comprises
one biomarker, that is platelet count [22], while the Khorana score, the PROTECHT score
and the CONKO score also include leukocyte count and haemoglobin level; meanwhile,
the COMPASS-CAT score also places more weight on cancer-related and patient-related
risk factors for VTE than the Khorana score and its variations do [17,20,21].
3.4. Models Developed in Ambulatory Patients with Lung Cancer
A dynamic model developed in NSCLC patients by Alexander et al. involves only two
biomarkers: baseline fibrinogen level and dynamic D-dimer levels at baseline and after one
month [51]. This risk model is described as three conditions: baseline fibrinogen ≥ 4.0 g/L
and baseline D-dimer ≥ 0.5 mg/L, baseline D-dimer ≥ 1.5 mg/L, and month-1
D-dimer ≥ 1.5 mg/L; each condition scores 1 point and a high risk is assigned if the
patient is receiving chemotherapy and the score ≥1 [51]. Seventy-two percent of a cohort
of outpatients with lung cancer had a high risk of thromboembolism, and the incidence
of thromboembolism at 6 months was 26.5% vs. 0% in the high- and low-risk groups,
respectively [51]. This model had a high sensitivity (100%, 95% CI 79–100%) but a low
specificity (34%, 95% CI 23–47%), while the discriminating capacity was moderate (C-index
0.67, 95% CI 0.61–0.73) [50]. This model may not be applicable in patients with lung cancer
who do not receive chemotherapy.
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The ROADMAP-CAT model, which was developed in outpatients with lung adeno-
carcinoma, involves laboratory parameters only, which are procoagulant phospholipid-
dependent clotting time (Procoag-PPL) and mean rate index (MRI) of thrombin genera-
tion [24]. This model is a binary scoring system: patients with Procoag-PPL < 44 s and
MRI < 125 nM/min are identified with a high risk of VTE, while those with
Procoag-PPL > 44 s or MRI > 125 nM/min are considered low risk [24]. The incidence
of VTE in a 6-month follow-up period was 12.2% and 3.4% in high- and low-risk groups,
respectively. The sensitivity was relatively high (88%), but the specificity was relatively
low (52%), with a C-index of 0.77 showing moderate discriminatory performance [24].
4. Risk of Bias in VTE Risk Model Development and Validation Studies
We used the Prediction model Risk Of Bias ASessment Tool (PROBAST) [64] to identify
potential biases in the development or validation of current VTE risk models. The first issue
is the small sample size of many studies. As a rule of thumb, for risk model development
studies, events per variable (EPV) should not be less than 10, while for risk model validation
studies, there should be more than 100 participants with the occurrence of the outcome,
in this case, VTE [65]. Secondly, dichotomisation of continuous predictors, such as white
cell count, platelet count, BMI, D-dimer and fibrinogen, occurs in almost all models, which
may lead to loss of linear information [65]. In addition, univariable analysis is a popular
approach for predictor selection; however, this may miss some important predictors that
are confounded by other predictors [65]. Furthermore, internal validation is necessary
for directing an adjustment to build a robust risk prediction model, but in the VTE risk
model development studies in ambulatory patients with lung cancer, internal validation
was overlooked [65].
Model overfitting in risk model development could arise from issues such as small
EPV, dichotomisation of continuous predictors, selecting predictors solely based on uni-
variable analysis, or lack of internal validation with bootstrapping or cross-validation in
the development studies. A lack of calibration is the next problem in both risk model
development and validation. Calibration indicates the accuracy of a risk model by show-
ing agreement between the expected number of events based on the risk model and the
observed number of events [66]. Calibration is indispensable in the external validation of
prognostic risk models, and calibration plots are even suggested at more than one time
point for those models with competing risks [67]. Last but not least, there is use of a derived
clinical score in risk models that does not reflect the actual weight of a predictor from
the multivariable analysis in VTE risk model development [51]. The logistic regression
equation is the actual expression of the risk model developed from the data [23].
Validation of VTE risk models should include patients receiving all currently ap-
proved medications, including anticoagulation therapies in this context. Ideally, a VTE
risk model to be used in cancer patients should also provide some hint as to the most
suitable medication to be used [68]. To address the growing clinical complexity, use of
novel technologies, such as information-technology-powered decision support systems
and Artificial Intelligence (AI) algorithms might be helpful both in the development and
the validation phases. In this regard, preliminary studies have recently provided promising
results [68,69].
5. Conclusions
Anticoagulant thromboprophylaxis in ambulatory patients with lung cancer could
be a life-saving treatment by preventing VTE. However, since this treatment increases
the risk of bleeding, it should be administered only in patients who are at a high risk of
developing thromboembolic events. In this literature review, we have discussed some of
the available risk prediction models for VTE which could be used in ambulatory patients
with lung cancer. The original Khorana score and its modifications may not be sensitive
enough to identify high-risk ambulatory patients with lung cancer. With the cut-off value
changing from 3 to 2 points, the Khorana score may be effective, but it needs to be validated
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in ambulatory patients with lung cancer. The COMPASS-CAT score and some other
developed risk models may be promising, but further validation is needed. Correct
statistical methods and processes, including sufficient sample size, pre-specified predictor
candidates, calibration plots and internal validation, should be considered and used in
both risk model development and validation studies to ensure a low risk of bias.
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